CN1389265A - 一种具有保健作用的中药组合物 - Google Patents
一种具有保健作用的中药组合物 Download PDFInfo
- Publication number
- CN1389265A CN1389265A CN 01118618 CN01118618A CN1389265A CN 1389265 A CN1389265 A CN 1389265A CN 01118618 CN01118618 CN 01118618 CN 01118618 A CN01118618 A CN 01118618A CN 1389265 A CN1389265 A CN 1389265A
- Authority
- CN
- China
- Prior art keywords
- group
- tried
- dosage
- influence
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title description 8
- 239000002131 composite material Substances 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 19
- 241000222336 Ganoderma Species 0.000 claims abstract description 9
- 241000241413 Propolis Species 0.000 claims abstract description 8
- 229940069949 propolis Drugs 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 9
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 7
- 244000293323 Cosmos caudatus Species 0.000 claims description 7
- 238000005728 strengthening Methods 0.000 abstract description 6
- 210000000988 bone and bone Anatomy 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 230000001256 tonic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 30
- 230000037396 body weight Effects 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 235000014655 lactic acid Nutrition 0.000 description 18
- 239000004310 lactic acid Substances 0.000 description 18
- 230000009182 swimming Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 230000000242 pagocytic effect Effects 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- -1 hydroxyl radical free radical Chemical class 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | 剂量(g/kg.Bw) | 动物数(只) | 胸腺/体重比值(mg/g) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 2.37±0.292.47±0.622.27±0.582.26±0.60 | -0.62450.60260.7130 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 脾脏/体重比值(mg/g) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 5.05±1.265.73±0.885.24±0.825.56±1.03 | -0.14340.66570.4095 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 实验前体重(g) | P值 | 实验后体重(g) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 19.3±1.119.5±1.519.1±0.819.2±0.8 | -0.75710.47930.6708 | 32.9±2.532.0±2.432.8±2.331.4±2.7 | -0.37400.94660.1677 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 淋巴细胞增殖能力 | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 0.032±0.0270.031±0.0250.047±0.0280.036±0.027 | -0.88320.24130.7352 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 足跖肿胀度差值(mm) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 0.57±0.280.46±0.240.54±0.200.52±0.19 | -0.53770.75310.8831 |
组别 | 剂量(g/kg,bw) | 动物数(只) | PFC | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 4.91±0.235.17±0.19**5.13±0.21*5.10±0.10* | -0.00710.02690.0171 |
组别 | 剂量(g/kg.bw) | 动物数(只) | HC50 | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 189.7±75.4255.6±23.2**229.1±51.1210.8±65.1 | -0.00840.14770.4707 |
组 别 | 剂量(g/kg.bw) | 动物数(只) | α | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 6.06±0.816.17±0.916.39±0.676.24±0.61 | -0.77080.29580.2385 |
组别 | 剂量(g/kg.bw) | 动物数(只) | 吞噬率(%) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 23±1036±9**43±14***35±8** | -0.00310.00040.0042 |
组 别 | 剂量(g/kg.bw) | 动物数(只) | 吞噬指数 | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 0.44±0.230.70±0.22**0.85±0.33**0.63±0.14* | -0.00850.00160.0205 |
动物分组 | 受试物剂量 动物数(g/kg.bw) (只) | 给受试物前体重(g) | P值 | 给受试物39天后体重(g) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 0 120.2 120.4 121.2 12 | 20.9±1.720.6±1.320.5±1.621.2±2.0 | -0.62290.59750.6573 | 38.3±5.236.2±2.338.1±5.037.9±4.9 | -0.21290.93090.8385 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 游泳时间(min) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 11.1±7.026.9±14.7**23.3±18.9*25.0±18.9* | -0.00270.04690.0255 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 爬杆时间(min) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 5.5±1.911.6±5.9**14.7±11.8*13.0±10.7* | -0.00250.01350.0263 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 血清尿素氮(mg/dL) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 25.6±3.523.1±4.025.4±2.322.2±3.7* | -0.10510.86970.0289 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 血乳酸浓度游泳前(mg/dL) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 15.7±4.812.9±4.815.2±4.115.1±5.2 | -0.16680.77150.7580 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 血乳酸浓度游泳后0min(mg/dL) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 41.7±12.743.9±10.152.9±26.744.9±8.6 | -0.65310.20400.4849 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 血乳酸浓度游泳后0min(mg/dL) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 16.1±4.416.5±5.915.5±5.513.4±4.7 | -0.83720.78330.1712 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 血乳酸升高比值 | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 1.84±1.152.79±1.462.76±2.132.32±1.32 | -0.09020.20100.3507 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 血乳酸消除比值 | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 0.58±0.180.61±0.120.66±0.170.70±0.10* | -0.55710.24120.0480 |
动物分组 | 受试物剂量(g/kg.bw) | 动物数(只) | 肝糖原(g/100g肝脏) | P值 |
空白对照组低剂量组中剂量组高剂量组 | 00.20.41.2 | 12121212 | 4.19±1.333.70±1.084.30±0.953.69±0.48 | -0.33690.82450.2289 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011186186A CN1166402C (zh) | 2001-06-05 | 2001-06-05 | 一种具有保健作用的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011186186A CN1166402C (zh) | 2001-06-05 | 2001-06-05 | 一种具有保健作用的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1389265A true CN1389265A (zh) | 2003-01-08 |
CN1166402C CN1166402C (zh) | 2004-09-15 |
Family
ID=4663316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011186186A Expired - Fee Related CN1166402C (zh) | 2001-06-05 | 2001-06-05 | 一种具有保健作用的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1166402C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103141836A (zh) * | 2013-02-21 | 2013-06-12 | 汤臣倍健股份有限公司 | 兼具增强免疫力功能的瘦身胶囊 |
CN104585732A (zh) * | 2014-12-30 | 2015-05-06 | 广州白云山汉方现代药业有限公司 | 一种灵芝孢子保健食品及其制备方法与缓解体力疲劳应用 |
CN107372954A (zh) * | 2017-07-28 | 2017-11-24 | 明光市昊昊蜂业有限公司 | 一种蜂胶美容养颜茶 |
CN108991453A (zh) * | 2018-08-06 | 2018-12-14 | 重庆市畜牧科学院 | 一种复方纳米蜂胶的制备方法及其产品 |
CN112618589A (zh) * | 2021-01-04 | 2021-04-09 | 王喆鑫 | 一种中药保健药品配方及其制作方法 |
-
2001
- 2001-06-05 CN CNB011186186A patent/CN1166402C/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103141836A (zh) * | 2013-02-21 | 2013-06-12 | 汤臣倍健股份有限公司 | 兼具增强免疫力功能的瘦身胶囊 |
CN104585732A (zh) * | 2014-12-30 | 2015-05-06 | 广州白云山汉方现代药业有限公司 | 一种灵芝孢子保健食品及其制备方法与缓解体力疲劳应用 |
CN107372954A (zh) * | 2017-07-28 | 2017-11-24 | 明光市昊昊蜂业有限公司 | 一种蜂胶美容养颜茶 |
CN108991453A (zh) * | 2018-08-06 | 2018-12-14 | 重庆市畜牧科学院 | 一种复方纳米蜂胶的制备方法及其产品 |
CN112618589A (zh) * | 2021-01-04 | 2021-04-09 | 王喆鑫 | 一种中药保健药品配方及其制作方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1166402C (zh) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1247121C (zh) | 一种含龙眼多糖和枸杞多糖保健液的制备方法 | |
CN1762236A (zh) | 一种能增强人体免疫力的保健食品及其制备方法 | |
CN1839827A (zh) | 雷尼酸锶咀嚼片及其制备方法 | |
CN106213492A (zh) | 一种提升运动机能并增加骨密度的健康产品及制备方法 | |
CN105125621A (zh) | 一种具有增强免疫等作用的口服组合物 | |
CN1799411A (zh) | 具有润肠通便功能的膳食纤维组合物及其生产方法 | |
CN1799409A (zh) | 具有减肥美容功能的膳食纤维组合物及其生产方法 | |
CN101352236B (zh) | 大果沙棘复合抗疲劳粉末及其制备方法 | |
CN1389265A (zh) | 一种具有保健作用的中药组合物 | |
CN1803015A (zh) | 一种具有免疫调节和抗疲劳功能保健食品的制备方法 | |
EP3381457B1 (de) | Physiologisch aktive zubereitung umfassend n-acetyl-glukosamin zur behandlung von rückenschmerzen | |
CN1217669C (zh) | 柚皮苷用于制备治疗咳嗽的药物 | |
DE20121186U1 (de) | Zusammensetzungen zur Nahrungsmittel- und Tierfutterergänzung | |
CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
CN1178688C (zh) | 一种抗疲劳的保健食品 | |
CN1526390A (zh) | 一种匹多莫德的颗粒剂及其制备方法 | |
CN1134298A (zh) | 治疗癫痫的中成药“癫痫宁息丸” | |
CN1883500A (zh) | 低分子柑桔果胶用于增强免疫功能的应用 | |
CN1253158C (zh) | 一种生物光素及其制备工艺 | |
CN101032524A (zh) | 洋虫在制备耐缺氧的药物或保健食品中的应用及制备方法 | |
CN1040063C (zh) | 葡萄糖酸锌在制备平喘镇咳药中的应用 | |
CN102356873A (zh) | 一种由西洋参和氨基葡萄糖制成的保健食品 | |
CN1277553C (zh) | 治疗运动性疲劳和慢性疲劳综合症的中成药 | |
CN1277570C (zh) | 治疗消化道溃疡疾病的药物及其制备方法 | |
DE60026816T2 (de) | Immunotrophische Preparation zur Behandlung von tonsillärer Hypertrophie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: BEIJING SHENGGUOTAI TECHNOLOGY CO., LTD. Free format text: FORMER NAME OR ADDRESS: BEIJING XIKAIGUOTAI MEDICINE SCI-TECH CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 100013, 28 North Third Ring Road, Beijing Yi Building, room 1608 Patentee after: Beijing Saint Pacific Science and Technology Co., Ltd. Address before: 100027 No. 7, Dongxing Road, Beijing, Chaoyang District Patentee before: Beijing Xikaiguotai Medicine Sci-Tech Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHANG MINGLI Free format text: FORMER OWNER: BEIJING SHENGGUOTAI TECHNOLOGY CO., LTD. Effective date: 20070105 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: 100102, room 1, unit 10, 601 south, Hua Fang, Chaoyang District, Beijing Patentee after: Zhang Mingli Address before: 100013, 28 North Third Ring Road, Beijing Yi Building, room 1608 Patentee before: Beijing Saint Pacific Science and Technology Co., Ltd. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040915 Termination date: 20140605 |